Glass-Related Drug Recalls Decline After Industry Improves Practices
The number of sterile drug recalls from glass delamination, breakage and other sources of contamination has dropped dramatically since 2010, with the exception of several spikes in 2013 and 2014. FDA and other officials attribute the drop to better risk assessments and fuller evaluations of product formulations' interactions with container closure systems. The industry is also exploring the use of a new, reportedly sturdier type of glass vial that eliminates delamination.
You may also be interested in...
Coronavirus Notebook: Remdesivir Supply Dwindles; US FDA Signs Another RWE Deal; Corning Gets BARDA Contract For Glass Vials
Dispatches from a world turned upside down also include changes in drug sample distribution guidelines and further reductions in the hours of FDA’s COVID hotline.
US Legislators Weaving Cybersecurity, National Stockpile Care Into Pandemics Bill
House Energy and Commerce Committee members crafting a pandemic-planning reauthorization bill are adding device cybersecurity details to the language to help maintain the nation’s stockpile of countermeasures to infectious disease outbreaks and chemical, nuclear and biological attacks.
Trump Lauds Big Pharma Collaboration On Super Strong Glass Packaging
President announces Merck, Pfizer and Corning collaboration on new glass packaging for injectable drugs as part of "Made In America Week;" says FDA is streamlining regulations.